Mahalo no kou kipa ʻana iā Nature.com.ʻO ka polokalamu kele pūnaewele āu e hoʻohana nei he kākoʻo CSS kaupalena.No ka ʻike maikaʻi loa, manaʻo mākou e hoʻohana i kahi polokalamu kele pūnaewele hou (a i ʻole e hoʻopau i ke ʻano Compatibility Mode ma Internet Explorer).I kēia manawa, e hōʻoia i ke kākoʻo mau ʻana, e hāʻawi mākou i ka pūnaewele me ka ʻole o nā ʻano a me JavaScript.
Hoʻohana nui ʻia nā peptides a me nā protein no ka mālama ʻana i nā maʻi like ʻole, akā maʻamau e hoʻopili ʻia lākou a pōkole ka hopena.Hiki ke hoʻopau ʻia kēia mau hemahema o nā hale maoli me ke kōkua o ka ʻenekinia molekula, akā he hana paʻakikī kēia.ʻO nā ʻenehana ʻenekinia molekula, i hoʻohana mua ʻia i ka insulin a i kēia manawa ua hoʻohana maikaʻi ʻia i kekahi mau biopharmaceuticals, koi i ka derivatization o nā peptides a me nā protein mai nā waikawa momona.Hiki i nā ʻano kikoʻī a me kahi o nā ʻakika momona i hoʻopili ʻia ke hāʻawi i nā ʻano hana elongation like ʻole.Eia hou, hiki i kēia ʻenehana ke hāʻawi i ka hapalua o ke ola ma hope o ka hoʻohana waha ʻana i nā lāʻau peptide, hiki ke hoʻololi i ka hāʻawi ʻana i nā peptides, a loaʻa paha ka mana no ka huli ʻana i nā kiko.Me ka palekana maoli o nā ʻakika momona a me nā waiwai kemika i wehewehe maikaʻi ʻia, hāʻawi kēia ʻenehana i kahi ala kūpono i ka peptide a me ka ʻike ʻana i ka lāʻau lapaʻau.
Uena na kumukuai a pau.E hoʻohui ʻia ka VAT ma hope i ka wā kūʻai.E hana ʻia nā helu ʻauhau ma ka hale kūʻai.
Muttenthaler, M., King, GF, Adams, DJ & Alewood, PF Trends in peptide drug discovery. Muttenthaler, M., King, GF, Adams, DJ & Alewood, PF Trends in peptide drug discovery.Muttenthaler, M., King, GF, Adams, DJ a me Alevud, PF Trends i ka ʻike lāʻau peptide. Muttenthaler, M., King, GF, Adams, DJ & Alewood, PF 多肽药物发现的趋势。 Muttenthaler, M., King, GF, Adams, DJ & Alewood, PFMuttenthaler, M., King, GF, Adams, DJ a me Alevud, PF Trends i ka ʻike lāʻau peptide.Lahui Ka wehe ana o ke kahunapule laau.20, 309–325 (2021).Ke nānā nei kēia loiloi i nā ʻano o kēia manawa a me ka wā e hiki mai ana o ka ʻike ʻana i ka lāʻau peptide.
Müller, TD, Blüher, M., Tschöp, MH & DiMarchi, RD ʻO ka loaʻa ʻana o ka lāʻau lapaʻau anti-obesity: holomua a me nā pilikia. Müller, TD, Blüher, M., Tschöp, MH & DiMarchi, RD ʻO ka loaʻa ʻana o ka lāʻau lapaʻau anti-obesity: holomua a me nā pilikia.Müller, TD, Blucher, M., Chop, MH a me DiMarchi, RD Anti-obesity ʻike lāʻau lapaʻau: holomua a me nā pilikia. Müller, TD, Blüher, M., Tschöp, MH & DiMarchi, RD 抗肥胖药物发现：进展和挑战。 Müller, TD, Blüher, M., Tschöp, MH & DiMarchi, RDMüller, TD, Blucher, M., Chop, MH a me DiMarchi, RD Anti-obesity ʻike lāʻau lapaʻau: holomua a me nā pilikia.Lahui Ka wehe ana o ke kahunapule laau.21, 201–223 (2022).Hāʻawi kēia loiloi i kahi ʻike i nā pilikia o ka momona, ʻoi aku ka manaʻo hou e pili ana i nā peptides.
ʻO Strohl, WR Fusion proteins e hoʻolōʻihi i ka hapalua o ke ola o ka biologics e like me ka hoʻolālā maikaʻi loa no ka biologics.Biopharmaceutics 29, 215–239 (2015).
Evans, M. et al.ʻO ka mālama ʻana a me ka hoʻomau ʻana o nā lāʻau antidiabetic a me ka hui pū ʻana me nā hopena lapaʻau a me ka hoʻokele waiwai i nā maʻi me ka maʻi diabetes type 2: kahi loiloi ʻōnaehana o ka palapala.ʻobesity diabetic.metabolism.24, 377–390 (2022).
Polonsky, WH, Fisher, L., Hessler, D., Bruhn, D. & Best, JH Nā manaʻo maʻi i nā lāʻau lapaʻau hoʻokahi pule no ka maʻi diabetes. Polonsky, WH, Fisher, L., Hessler, D., Bruhn, D. & Best, JH Nā manaʻo maʻi i nā lāʻau lapaʻau hoʻokahi pule no ka maʻi diabetes.Polonsky WH, Fisher L., Hessler D., Brune D., a me ka Best JH He manaʻo o ka mea maʻi i nā lāʻau maʻi diabetes i hoʻokahi pule. Polonsky, WH, Fisher, L., Hessler, D., Bruhn, D. & Best, JH 患者对每周一次的糖尿病药物的看法。 Polonsky, WH, Fisher, L., Hessler, D., Bruhn, D. & Best, JHPolonsky WH, Fisher L., Hessler D., Brune D., a me ka ʻike maʻi maikaʻi loa ʻo JH o nā lāʻau maʻi diabetes i hoʻokahi pule.ʻobesity diabetic.metabolism.13, 144–149 (2011).
Hashimoto, M., Takada, K., Kiso, Y. & Muranishi, S. Synthesis of palmitoyl derivatives of insulin and their biological activities. Hashimoto, M., Takada, K., Kiso, Y. & Muranishi, S. Synthesis of palmitoyl derivatives of insulin and their biological activities.Hashimoto M., Takada K., Kiso Y. a me Muranishi S. Synthesis of palmitoyl derivatives of insulin and their biological activity. Hashimoto, M., Takada, K., Kiso, Y. & Muranishi, S. 胰岛素棕榈酰衍生物的合成及其生物活性。 Hashimoto, M., Takada, K., Kiso, Y. & Muranishi, S. Synthesis and biological activity of insulin palmitoyl derivatives.Hashimoto M., Takada K., Kiso Y. a me Muranishi S. Synthesis a me ka hana olaola o ka insulin palmitoyl derivatives.waihona lāʻau 6, 171–176 (1989).
Kurtzhals, P. et al.ʻO ka Albumin e hoʻopaʻa ana i ka insulin acid-acylate: ke ʻano o ka pilina ligand-protein a me ka pilina ma waena o ka pilina paʻa a me ka manawa hana insulin i vivo.biochem.J. 312, 725–731 (1995).ʻO kēia hana ka mea mua i hōʻike i ka piʻi ʻana o ka hapalua o ke ola ma muli o ka hoʻopaʻa ʻana o albumin i nā peptides i loaʻa mai nā momona momona.
Mejuch, T. & Waldmann, H. Synthesis of lipidated proteins. Mejuch, T. & Waldmann, H. Synthesis of lipidated proteins.Meyukh, T. a me Waldmann, H. Synthesis of lipidated proteins. Mejuch, T. & Waldmann, H. 脂化蛋白质的合成。 Mejuch,T.& Waldmann,H.Meyukh, T. a me Waldmann, H. Synthesis of lipidated proteins.Bioconjugate.Kemika.27, 1771–1783 (2016).
Chen, B., Sun, Y., Niu, J., Jarugumilli, GK & Wu, X. Protein lipidation i ka hōʻailona cell a me nā maʻi: hana, hoʻoponopono, a me nā manawa kūpono. Chen, B., Sun, Y., Niu, J., Jarugumilli, GK & Wu, X. Protein lipidation i ka hōʻailona cell a me nā maʻi: hana, hoʻoponopono, a me nā manawa kūpono.Chen B., Sun Y., Niu J., Jarugumilli GK a me Wu X. Protein lipidation i ka hōʻailona cell a me ka maʻi: hana, hoʻoponopono, a me ka hiki ke hoʻoponopono. Chen, B., Sun, Y., Niu, J., Jarugumilli, GK & Wu, X. Chen, B., Sun, Y., Niu, J., Jarugumilli, GK & Wu, X. Protein脂化 i ka hōʻailona cell a me ka maʻi: hana, hoʻoponopono a me nā manawa kūpono.Chen B., Sun Y., Niu J., Jarugumilli GK a me Wu X. Protein lipidation i ka hōʻailona cell a me ka maʻi: hana, hoʻoponopono, a me ka hiki ke hoʻoponopono.cytochemistry.biology 25, 817–831 (2018).
Richter, WF, Bhansali, SG & Morris, ME Mechanistic determinants o ka biotherapeutics absorption ma hope o ka hoʻokele SC. Richter, WF, Bhansali, SG & Morris, ME Mechanistic determinants o ka biotherapeutics absorption ma hope o ka hoʻokele SC.Richter, VF, Bhansali, SG a me Morris, ME Mechanisms e hoʻoholo i ka absorption o nā mea biotherapeutic ma hope o ka hoʻokele subcutaneous. Richter, WF, Bhansali, SG & Morris, ME SC 给药后生物治疗药物吸收的机制决定因素。 Richter, WF, Bhansali, SG & Morris, ME SC Richter, WF, Bhansali, SG & Morris, ME SC Механистические детерминанты абсорбции биотерапевтических препаратов после введения. Richter, WF, Bhansali, SG & Morris, ME SC Nā mea hoʻoholo mīkini o ka absorption o nā lāʻau biotherapeutic ma hope o ka lawelawe ʻana.AAPS J. 14, 559–570 (2012).
Gradel, AKJ et al.ʻO nā mea e pili ana i ka absorption insulin subcutaneous: nā hopena no ka loli.J. Diabetes Res.2018, 1205121 (2018).
Hildebrandt, P., Sejrsen, P., Nielsen, SL, Birch, K. & Sestoft, L. Hoʻoholo ka diffusion a me ka polymerization i ka absorption insulin mai ke kino subcutaneous i nā maʻi diabetic. Hildebrandt, P., Sejrsen, P., Nielsen, SL, Birch, K. & Sestoft, L. Hoʻoholo ka diffusion a me ka polymerization i ka absorption insulin mai ke kino subcutaneous i nā maʻi diabetic. Hildebrandt, P., Sejrsen, P., Nielsen, SL, Birch, K. & Sestoft, L м. Hildebrandt, P., Sejrsen, P., Nielsen, SL, Birch, K. & Sestoft, L. Hoʻoholo ka diffusion a me ka polymerization i ka absorption insulin mai ke kino subcutaneous i nā maʻi diabetic. Hildebrandt, P., Sejrsen, P., Nielsen, SL, Birch, K. & Sestoft, L. 扩散和聚合决定了糖尿病患者皮下组织对胰岐的。 Hildebrandt, P., Sejrsen, P., Nielsen, SL, Birch, K. & Sestoft, L. Hildebrandt, P., Sejrsen, P., Nielsen, SL, Birch, K. & Sestoft, L . Hildebrandt, P., Sejrsen, P., Nielsen, SL, Birch, K. & Sestoft, L. Hoʻoholo ka diffusion a me ka hui ʻana i ka absorption insulin subcutaneous i nā maʻi maʻi maʻi.ka nānā ʻana.J. Klin.hale hoʻokolohua.hoʻokomo kālā.45, 685–690 (1985).
Mosekilde, E., Jensen, KS, Binder, C., Pramming, S. & Thorsteinsson, B. Ke hoʻohālike nei i nā kinetics absorption o subcutaneous injected soluble insulin. Mosekilde, E., Jensen, KS, Binder, C., Pramming, S. & Thorsteinsson, B. Ke hoʻohālike nei i nā kinetics absorption o subcutaneous injected soluble insulin.Mosekilde E, Jensen KS, Binder S, Pramming S, a me Thorsteinsson B. Hoʻohālike i nā kinetics absorption o ka insulin soluble subcutaneous. Mosekilde, E., Jensen, KS, Binder, C., Pramming, S. & Thorsteinsson, B. 模拟皮下注射可溶性胰岛素的吸收动力学。 Mosekilde, E., Jensen, KS, Binder, C., Pramming, S. & Thorsteinsson, B.Mosekilde E, Jensen KS, Binder S, Pramming S, a me Thorsteinsson B. Hoʻohālike i nā kinetics absorption o ka insulin soluble i lawelawe ʻia ma lalo o ke kino.J. Pharmacokinetics.biopharmacy.17, 67–87 (1989).
Kuna, M., Mahdi, F., Chade, AR & Bidwell, GL III Molecular size modulates pharmacokinetics, biodistribution, and renal deposition of the drug delivery biopolymer elastin-like polypeptide. Kuna, M., Mahdi, F., Chade, AR & Bidwell, GL III Molecular size modulates pharmacokinetics, biodistribution, and renal deposition of the drug delivery biopolymer elastin-like polypeptide. Kuna, M., Mahdi, F., Chade, AR & Bidwell, GL III ого полипептида для доставки лекарственного средства. Kuna, M., Mahdi, F., Chade, AR & Bidwell, GL III Molecular size modulates pharmacokinetics, biodistribution, and renal deposition of biopolymeric elastin-like polypeptide for drug delivery. Kuna, M., Mahdi, F., Chade, AR & Bidwell, GL III和肾脏沉积。 Kuna, M., Mahdi, F., Chade, AR & Bidwell, GL III MoleculeKuna, M., Mahdi, F., Chad, AR a me Bidwell, GL III.Pharmacokinetics, biodistribution a me renal deposition o biopolymeric elastin-like polypeptides modulating i ka nui o ka mole.Hōʻike ʻepekema 8, 7923 (2018).
Harris, JM, Martin, NE & Modi, M. Pegylation: kahi hana hou no ka hoʻololi ʻana i nā pharmacokinetics. Harris, JM, Martin, NE & Modi, M. Pegylation: kahi hana hou no ka hoʻololi ʻana i nā pharmacokinetics. Harris, JM, Martin, NE & Modi, M. Пегилирование: новый процесс модификации фармакокинетики. Harris, JM, Martin, NE & Modi, M. Pegylation: kahi hana hou no ka hoʻololi ʻana i nā pharmacokinetics. Harris, JM, Martin, NE & Modi, M. 聚乙二醇化：一种改变药代动力学的新方法。 Harris, JM, Martin, NE & Modi, M. 聚乙二感化: kahi ala hou e hoʻololi ai i ka lāʻau lapaʻau. Harris, JM, Martin, NE & Modi, M. Пегилирование: новый подход к изменению фармакокинетики. Harris, JM, Martin, NE & Modi, M. Pegylation: kahi ala hou e hoʻololi ai i nā pharmacokinetics.lāʻau lapaʻau.Pharmacokinetics.40, 539–551 (2001).
Elmerer, M. et al.ʻO ke ana o ka albumin interstitial i loko o ka ʻiʻo iwi iwi a me ka ʻiʻo adipose e ka microperfusion wehe.ʻAe.J. Pilikino.endocrine.metabolism.278, E352-E356 (2000).
Nelson, J. et al.ʻO ka hapalua o ke ola o ka albumin i loko o ke kanaka e pono ai i kahi C-terminus paʻa.kamaʻilio.biology.3, 181 (2020).
Chowdhury, K. et al.ʻO ka mea hoʻokipa Fc (FcRn) no IgG pili me ka paʻakikī histocompatibility nui e hoʻopaʻa i ka albumin a hoʻolōʻihi i kona ola.J. Exp.lāʻau lapaʻau.197, 315–322 (2003).
Ober, RJ, Martinez, C., Lai, X., Zhou, J. & Ward, ES Exocytosis o IgG e like me ka mediated e ka mea loaʻa, FcRn: he loiloi ma ka pae hoʻokahi-molele. Ober, RJ, Martinez, C., Lai, X., Zhou, J. & Ward, ES Exocytosis o IgG e like me ka mediated e ka mea loaʻa, FcRn: he loiloi ma ka pae hoʻokahi-molele. Ober, RJ, Martinez, C., Lai, X., Zhou, J. & Ward, ES Экзоцитоз IgG, опосредованный рецептором FcRn: анализ на уровне одной молекулы. Ober, RJ, Martinez, C., Lai, X., Zhou, J. & Ward, ES FcRn receptor-mediated IgG exocytosis: hoʻokahi-molele analysis. Ober, RJ, Martinez, C., Lai, X., Zhou, J. & Ward, ES 受体介导的IgG 胞吐作用，FcRn：单分子水平的分析。 Ober, RJ, Martinez, C., Lai, X., Zhou, J. & Ward, ES Ober, RJ, Martinez, C., Lai, X., Zhou, J. & Ward, Экзоцитоз IgG, опосредованный рецептором ES, FcRn: анализ на уровне одной молеклы. Ober, RJ, Martinez, C., Lai, X., Zhou, J. & Ward, ES receptor-mediated IgG exocytosis, FcRn: hoʻokahi mole-level analysis.kaʻina hana.National Academy of Science.ka ʻepekema.US 101, 11076 (2004).
ʻO ia, XM & Carter, DC Atomic structure a me ke kemika o ke kanaka serum albumin. ʻO ia, XM & Carter, DC Atomic structure a me ke kemika o ke kanaka serum albumin.On, XM and Carter, DC Atomic structure and chemistry of human serum albumin. He, XM & Carter, DC 人血清白蛋白的原子结构和化学。 ʻO ia, XM & Carter, DC.On, XM and Carter, DC Atomic structure and chemistry of human serum albumin.Nature 358, 209–215 (1992).
ʻO Curry, S., Mandelkow, H., Brick, P. & Franks, N. ʻO ke ʻano kristal o ka albumin serum kanaka i hoʻopili ʻia me ka waikawa momona e hōʻike ana i kahi mahele like ʻole o nā wahi paʻa. ʻO Curry, S., Mandelkow, H., Brick, P. & Franks, N. ʻO ke ʻano kristal o ka albumin serum kanaka i hoʻopili ʻia me ka waikawa momona e hōʻike ana i kahi mahele like ʻole o nā wahi paʻa.ʻO Curry S., Mandelkow H., Brick P. a me Franks N. ʻO ke ʻano aniani o ka albumin serum kanaka i loko o ka paʻakikī me kahi momona momona e hōʻike ana i ka mahele like ʻole o nā wahi paʻa. Curry, S., Mandelkow, H., Brick, P. & Franks, N. ʻO Curry, S., Mandelkow, H., Brick, P. & Franks, N. ʻO ke ʻano aniani o ka paʻakai keʻokeʻo keʻokeʻo kanaka me nā ʻakika momona e hōʻike ana i ka mahele asymmetric o nā wahi paʻa.ʻO Curry S., Mandelkow H., Brick P. a me Franks N. ʻO ke ʻano aniani o ka albumin serum kanaka i loko o ka paʻakikī me nā ʻakika momona e hōʻike ana i kahi mahele asymmetric o nā wahi paʻa.Nat.hale kūkulu.biology 5, 827–835 (1998).Hōʻike kēia pepa i ke kumu hoʻonohonoho o ka hoʻopaʻa ʻana i nā ʻakika momona i ka albumin serum.
Irby, D., Du, C. & Li, F. Lipid-lāʻau conjugate no ka hoʻonui ʻana i ka lawe ʻana i ka lāʻau. Irby, D., Du, C. & Li, F. Lipid-lāʻau conjugate no ka hoʻonui ʻana i ka lawe ʻana i ka lāʻau.Irby, D., Du, K. a me Li, F. Lipid-lāʻau conjugates no ka hoʻonuiʻana i ka lāʻau. Irby, D., Du, C. & Li, F. Lipid-lāʻau conjugate no ka hoʻonui ʻana i ka lawe lāʻau. Irby, D., Du, C. & Li, F. Lipid-lāʻau conjugate no ka hoʻonui ʻana i ka lawe lāʻau.Irby, D., Du, K. a me Li, F. Lipid-lāʻau conjugate no ka hoʻonuiʻana i ka lāʻau.Biochemistry 14, 1325–1338 (2017).
ʻO Torchilin VP Ke holomua nei i ke kahua o nā liposomes ma ke ʻano he lawe lāʻau.Lahui Ka wehe ana o ke kahunapule laau.4, 145–160 (2005).
Bhat, M., Jatyan, R., Mittal, A., Mahato, RI & Chitkara, D. Nā manawa kūpono a me nā pilikia o ka momona momona conjugated therapeutics. Bhat, M., Jatyan, R., Mittal, A., Mahato, RI & Chitkara, D. Nā manawa kūpono a me nā pilikia o ka momona momona conjugated therapeutics.Bhat, M., Jatyan, R., Mittal, A., Mahato, RI a me Chitkara, D. Nā manawa kūpono a me nā pilikia o ka momona momona conjugated therapeutics. Bhat, M., Jatyan, R., Mittal, A., Mahato, RI & Chitkara, D. 脂肪酸共轭疗法的机遇和挑战。 Bhat, M., Jatyan, R., Mittal, A., Mahato, RI & Chitkara, D. Fatty acid 共续电影的机遇和challenge.Bhat M., Jatyan R., Mittal A., Mahato RI a me Chitkara D. Nā mea hiki a me nā pilikia o ka hoʻomaʻamaʻa ʻana i ka momona momona.Kemika.physics Lipid 236, 105053 (2021).
Smith, R. & Tanford, C. Hydrophobicity o ke kaulahao loloa n-alkyl carboxylic acids, e like me ke ana ana ma ko lakou mahele ana ma waena o ka heptane a me ka wai. Smith, R. & Tanford, C. Hydrophobicity o ke kaulahao loloa n-alkyl carboxylic acids, e like me ke ana ana ma ko lakou mahele ana ma waena o ka heptane a me ka wai.Smith, R. a me Tanford, K. Hydrophobicity o nā kaulahao lōʻihi n-alkylcarboxylic acids i ana ʻia e ko lākou māhele ʻana ma waena o ka heptane a me ka wai. Smith, R. & Tanford, C. 长链正烷基羧酸的疏水性，通过它们在庚烷和水溶液之间的分布来测量。 Smith, R. & Tanford, C. ʻO ka hydrophobicity o 长链正alkylcarboxylate, i ana ʻia e ko lākou mahele ʻana ma waena o ka hydrogen peroxide a me ka wai wai.Smith, R. a me Tanford, K. Hydrophobicity o nā kaulahao lōʻihi n-alkylcarboxylic acids i ana ʻia e ko lākou māhele ʻana ma waena o ka heptane a me ka wai.kaʻina hana.National Academy of Sciences.ʻepekema US 70, 289 (1973).
Liu, J. et al.ʻIke ʻia i hoʻokahi pule o ka analog semaglutide o glucagon-like peptide-1 (GLP-1).J. Laau lapaau.Kemika.58, 7370–7380 (2015).Hōʻike kēia hana no ka manawa mua i ka hiki ke hoʻohana i hoʻokahi manawa i ka pule i nā ʻano derivatization fatty acid.
Østergaard, S. et al.Ka hopena o ke kanaka PYY3-36 dibasic fatty acid acylation ma ka hana liʻiliʻi puaʻa Y2 a me ka hapalua o ke ola.ka ʻepekema.Hōʻike 11, 21179 (2021).Hōʻike kēia ʻatikala i ke koʻikoʻi o ke kūlana fatty acid, ka loulou a me ka paʻa o ka iwi kuamoʻo i ka hoʻomohala ʻana i nā analogs PYY lōʻihi hapalua-ola.
Ensenat-Vaser, R. et al.Ua nānā pono ʻia ke komo ʻana o nā peptides myristoylated ma waena o ka membrane cell me ka hoʻohana ʻana i ka microscopy fluorescence confocal.IUBMB Life 54, 33–36 (2002).
Nelson, AR, Borland, L., Allbritton, NL & Sims, CE ʻO ka lawe ʻana i nā peptides e pili ana i Myristoyl i loko o nā cell ola. Nelson, AR, Borland, L., Allbritton, NL & Sims, CE ʻO ka lawe ʻana i nā peptides e pili ana i Myristoyl i loko o nā cell ola.Nelson AR, Borland L, Allbritton NL.a me Sims SE Peptide ka lawe ʻana i loko o nā keena ola e pili ana i ka myristoyl. Nelson, AR, Borland, L., Allbritton, NL & Sims, CE 基于肉豆蔻酰的肽转运到活细胞中。 Nelson, AR, Borland, L., Allbritton, NL & Sims, CE.Nelson, AR, Borland, L., Albritton, NL.a me Sims, KE Ka lawe ʻana i nā peptides i hoʻokumu ʻia myristoyl i loko o nā cell ola.Biochemistry 46, 14771–14781 (2007).
Kabanov, AV, Levashov, AV & Alakhov, VY Lipid hoʻololi o nā protein a me kā lākou lawe membrane. Kabanov, AV, Levashov, AV & Alakhov, VY Lipid hoʻololi o nā protein a me kā lākou lawe membrane.Kabanov AV, Levashov AV, Alakhov V.Yu.ʻO ka hoʻololi ʻana o ka lipid o nā protein a me kā lākou lawe membrane. Kabanov, AV, Levashov, AV & Alakhov, VY 蛋白质的脂质修饰及其膜转运。 Kabanov, AV, Levashov, AV & Alakhov, VYKabanov AV, Levashov AV, Alakhov, Lipid hoʻololi o nā protein VY a me kā lākou lawe membrane.ʻenekinia protein.Dek. Searl.3, 39–42 (1989).
ʻO Gao, X., Mazière, AD, Beard, R., Klumperman, J. & Hannoush, RN Fatty acylation e hoʻonui i ka internalization cellular a me ka hāʻawi cytosolic o kahi peptide cystine-knot. ʻO Gao, X., Mazière, AD, Beard, R., Klumperman, J. & Hannoush, RN Fatty acylation e hoʻonui i ka internalization cellular a me ka hāʻawi cytosolic o kahi peptide cystine-knot.Gao, X., Mazier, AD, Byrd, R., Klumperman, J. a me Hannoosh, RN Fatty acid acylation e hoʻonui i ka internalization cellular a me ka hāʻawi cytosolic o kahi peptide me kahi loop cystine. Gao, X., Mazière, AD, Beard, R., Klumperman, J. & Hannoush, RN 脂肪酰化增强了胱氨酸结肽的细胞内化和胞质分布。 Gao, X., Mazière, AD, Beard, R., Klumperman, J. & Hannoush, RN.Gao, X., Mazier, AD, Byrd, R., Klumperman, J. a me Hannoosh, RN Fatty acylation e hoʻonui i ka internalization cellular a me ka hāʻawi cytoplasmic o nā peptides cystine.iScience 24, 103220 (2021).
Baker, EM et al.ʻO ka hoʻololi ʻana i ka hapalua o ke ola o ka peptide YY3-36 no ka internalization i hoʻopaʻa ʻia i ka mea hoʻokipa.Moore.lāʻau lapaʻau.16, 3665–3677 (2019).
Mäde, V., Bellmann-Sickert, K., Kaiser, A., Meiler, J. & Beck-Sickinger, AG ʻO ke kūlana a me ka lōʻihi o nā momona momona e hoʻopili ikaika i ke ʻano koho koho o nā analogues polypeptide pancreatic kanaka. Mäde, V., Bellmann-Sickert, K., Kaiser, A., Meiler, J. & Beck-Sickinger, AG ʻO ke kūlana a me ka lōʻihi o nā momona momona e hoʻopili ikaika i ke ʻano koho koho o nā analogues polypeptide pancreatic kanaka.Hana ʻia, W., Bellmann-Sickert, K., Kaiser, A., Mailer, J. a me Beck-Sickinger, AG ʻO ke kūlana a me ka lōʻihi o nā momona momona e hoʻoikaika ikaika i ke ʻano koho o nā pancreatic polypeptide analog receptors. M kade, V., Belmann-Salmonn-Solirton, K., Elois, J. - 位置受体多 人 的 受体受体多 人 的 受体受体模式. Mäde, V., Bellmann-Sickert, K., Kaiser, A., Meiler, J. & Beck-Sickinger, AGHana ʻia, W., Bellmann-Sickert, K., Kaiser, A., Mailer, J. a me Beck-Sickinger, AG ʻO ke kūlana a me ka lōʻihi o nā momona momona e hoʻoikaika nui i ke ʻano koho o nā pancreatic analog polypeptide receptors.HimMedChem 9, 2463–2474 (2014).
Aleksopoulou, F. et al.ʻO ka lipid metabolite PrRP31 kahi hana lōʻihi GPR10 a me NPFF2 receptor agonist me nā hopena pohō kaumaha.ka ʻepekema.Hōʻike 12, 1696 (2022).Hōʻike kēia haʻawina hoʻonaʻauao i ka ʻokoʻa ma waena o nā kaulahao ʻaoʻao mono a me ka diacid.
Poulsen, K. et al.Hoʻomohala kūpono o nā agonists paʻa o ka Y2 receptor peptide PYY3-36.lāʻau lapaʻau.pahu waihona.38, 1369–1385 (2021).
Conde-Frieboes, K. et al.ʻO ka ʻike a me ke ʻano o ka in vitro a in vivo analogues o ka hana lōʻihi a me ke koho melanocortin 4 receptor (MC4-R) alpha-melanocyte-stimulating hormone (alpha-MSH).J. Laau lapaau.Kemika.55, 1969–1977 (2012).
Ramirez-Andersen, HS et al.ʻO nā analogues ulu ulu kanaka lōʻihi i hoʻopaʻa ʻia i ka albumin non-covalent.Bioconjugate.Kemika.29, 3129–3143 (2018).
Madsen, K. et al.Ka pilina hana-hana a me ka lōʻihi o ka glucagon-like peptide-1 derivatives: ke koʻikoʻi o ka lōʻihi o ka momona momona, polarity, a me ka nui.J. Laau lapaau.Kemika.50, 6126–6132 (2007).
Wieczorek, B., Spetzler, JC, Kruse, T., Linderoth, L. & Kofoed, J. Nā hua hua GLP-1 pālua-acylate. Wieczorek, B., Spetzler, JC, Kruse, T., Linderoth, L. & Kofoed, J. Nā hua hua GLP-1 pālua-acylate. Wieczorek, B., Spetzler, JC, Kruse, T., Linderoth, L. & Kofoed, J. Дважды ацилированные производные GLP-1. Wieczorek, B., Spetzler, JC, Kruse, T., Linderoth, L. & Kofoed, J. Nā huaʻai acylated pālua o GLP-1. Wieczorek, B., Spetzler, JC, Kruse, T., Linderoth, L. & Kofoed, J. 双酰化GLP-1 衍生物。 Wieczorek, B., Spetzler, JC, Kruse, T., Linderoth, L. & Kofoed, J. 双酰化GLP-1 衍生物。 Wieczorek, B., Spetzler, JC, Kruse, T., Linderoth, L. & Kofoed, J. Диацилированные производные GLP-1. Wieczorek, B., Spetzler, JC, Kruse, T., Linderoth, L. & Kofoed, J. Diacylated derivatives o GLP-1.US Patent WO2012/140117 (2012).
Opio, P.-Yu.E kali.ʻO nā analogs GLP-1 ikaika a lōʻihi i hoʻolālā ʻia no ka lawe transdermal e pili ana i ka microstructure.kaʻina hana.National Academy of Science.ka ʻepekema.US 113, 4140–4145 (2016).
Royalty, JE, Konradsen, G., Eskerod, O., Wulff, BS & Hansen, BS Investigation of safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of a long-acting α-MSH analog in healthy overweight and obese nā kumuhana. Royalty, JE, Konradsen, G., Eskerod, O., Wulff, BS & Hansen, BS Investigation of safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of a long-acting α-MSH analog in healthy overweight and obese nā kumuhana.Royalty, JE, Konradsen, G., Eskerod, O., Wolf, BS a me Hansen, BS Safety, tolerability, pharmacokinetics, and pharmacodynamics study of single and multiple doses of long-acting α-MSG analog in health overweight and obese subjects.版税, JE, Konradsen, G., Eskerod, O., Wulff, BS & Hansen, BS 单剂量和多剂量长效α-MSH 类似物在健康超釀剂量和多剂量长效α-MSH 类似物在健康超釀善和超、耐受性、药代动力学和药效学研究科目。版税, JE, Konradsen, G., Eskerod, O., Wulff, BS & Hansen, BS Hoʻokahi kaʻina a me ka nui o ka hopena lōʻihi α-MSH 全健康超重和肥胖可以中可以可以中可以可以中可以可以可以可以而老和药效学研究科目。Royalty, JE, Konradsen, G., Eskerod, O., Wolf, BS a me Hansen, BS Safety, tolerability, pharmacokinetics o hoʻokahi a me ka nui o nā analogues alpha-MSG hana lōʻihi i nā kumuhana olakino a me ka momona.Kinetics a me ka pharmacodynamics.J. Clin.Pharmacodynamics.54, 394–404 (2014).
Lau, J., F., Kruse, T., Linderoth, L. & Thøgersen, H. Novel glucagon analogues. Lau, J., F., Kruse, T., Linderoth, L. & Thøgersen, H. Novel glucagon analogues.Lau, J., F., Kruse, T., Linderoth, L. a me Togersen, H. New glucagon analogues. Lau, J., F., Kruse, T., Linderoth, L. & Thøgersen, H. 新型胰高血糖素类似物。 Lau, J., F., Kruse, T., Linderoth, L. & Thøgersen, H.Lau, J., F., Cruz, T., Linderoth, L. a me Togersen, H. New glucagon analogues.US Patent WO2011/117416 A1 (2011).
Ward, BP et al.Hoʻopaʻa ka lipidation o nā peptides i nā hale e hoʻomaikaʻi i ka hana biological.Moore.metabolism.2, 468–479 (2013).Hōʻike kēia hana i ke kuleana o nā kaulahao ʻaoʻao momona momona i ka hoʻoholo ʻana i ke kūpaʻa o ke kūkulu ʻana a me ka hoʻopaʻa ʻana o nā mea hoʻopaʻa lāʻau peptide.
Koskun T. et al.LY3298176, kahi moʻolelo ʻelua GIP a me GLP-1 receptor agonist no ka mālama ʻana i ka maʻi maʻi type 2: mai ka ʻike ʻana i ka hōʻoia o ka manaʻo.Moore.metabolism.18, 3-14 (2018).Hōʻike kēia pepa i ka hoʻolālā ʻana o ka mea mua i loaʻa i ka momona momona GLP-1/GIP co-agonist no hoʻokahi pule pule ma ke keʻena.
Kjeldsen, TB et al.ʻO ka ʻenekinia molekula o ka insulin icodec, ka analog insulin acylated mua i hoʻokahi pule i ke kanaka.J. Laau lapaau.Kemika.64, 8942–8950 (2021).Hōʻike kēia pepa i ka hoʻomohala mua ʻana o ka ʻakika momona i loaʻa i ka insulin no hoʻokahi pule pule.
van Witteloostein, SB et al.ʻO Neoglycolipids no nā peptides lōʻihi: hoʻohui ponoʻī iā ia iho o ka glucagon-like peptide 1 me nā waiwai paʻa albumin a kiʻekiʻe i ka vivo potency.Moore.lāʻau lapaʻau.14, 193–205 (2017).
Zorzi, A., Middendorp, SJ, Wilbs, J., Deyle, K. & Heinis, C. Acylated heptapeptide e hoʻopaʻa i ka albumin me ka pilina kiʻekiʻe a me ka hoʻohana ʻana e like me ka hoʻolako ʻana i nā peptides lōʻihi. Zorzi, A., Middendorp, SJ, Wilbs, J., Deyle, K. & Heinis, C. Acylated heptapeptide e hoʻopaʻa i ka albumin me ka pilina kiʻekiʻe a me ka hoʻohana ʻana e like me ka hoʻolako ʻana i nā peptides lōʻihi.ʻO Zorzi, A., Middendorp, SJ, Wilbs, J., Dale, K. a me Haynes, S. Acylate heptapeptide e hoʻopaʻa i ka albumin me ka pilina kiʻekiʻe, aʻo kona hoʻohanaʻana ma keʻano he lepili e hāʻawi i kahi peptide lōʻihi. Zorzi, A., Middendorp, SJ, Wilbs, J., Deyle, K. & Heinis, C. Zorzi, A., Middendorp, SJ, Wilbs, J., Deyle, K. & Heinis, C.Zorzi, A., Middendorp, SJ, Wilbs, J., Dale, K. a me Haynes, S. Acylated heptapeptides hoʻopaʻa i ka albumin me ka pilina kiʻekiʻe a lilo i mau lepili no ka lawe ʻana i ka peptide lōʻihi.Nat.kamaʻilio 8, 16092 (2017).
Ka manawa hoʻouna: Sep-08-2022
